To improve patient stratification for immunotherapy, the analysis of immuno-oncology biomarkers, like PD-L1, as well as a more comprehensive analysis of the immune and tumor-related pathways (the “Cancer Immunogram) (Fig. 2) [4] has to be used for a better patient stratification in future immunotherapy trials [5]. This evidence concerns the gene CD274 and neoplasm.